Identification

Name
Budesonide
Accession Number
DB01222  (APRD00442)
Type
Small Molecule
Groups
Approved
Description

Budesonide is a glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis. [PubChem] The extended release oral tablet, marketed as Uceris, was FDA approved on January 14, 2013 for the management of ulcerative colitis. Budesonide is provided as a mixture of two epimers (22R and 22S). Interestingly, the 22R form is two times more active than the 22S epimer. The two forms do not interconvert.

Structure
Thumb
Synonyms
  • (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BudesonideCapsule3 mg/1OralPaddock Laboratories, Inc.2018-06-29Not applicableUs
BudesonideSpray, metered32 ug/1NasalAstra Zeneca Lp2014-05-132018-02-28Us
CortimentTablet, extended release9 mgOralFerring Pharmaceuticals2016-07-25Not applicableCanada
EntocortCapsule, extended release3 mgOralTillotts Pharma Gmbh1997-01-30Not applicableCanada
Entocort ECCapsule3 mg/1OralPhysicians Total Care, Inc.2006-05-22Not applicableUs65483 0702 10 nlmimage10 f6387b33
Entocort ECCapsule3 mg/1OralPrometheus Laboratories2001-10-29Not applicableUs
Entocort ECCapsule3 mg/1OralAstra Zeneca Lp2001-10-02Not applicableUs
Entocort ECCapsule3 mg/1OralPaddock Laboratories, Inc.2001-10-29Not applicableUs
Pulmicort FlexhalerAerosol, powder90 ug/1Respiratory (inhalation)Rebel Distributors2010-07-30Not applicableUs
Pulmicort FlexhalerAerosol, powder180 ug/1Respiratory (inhalation)A S Medication Solutions2007-03-192017-06-20Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Physicians Total Care, Inc.2009-02-04Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2009-02-04Not applicableUs
BudesonideCapsule, coated pellets3 mg/1OralNorthstar Rx Llc.2018-06-25Not applicableUs
BudesonideCapsule, coated pellets3 mg/1OralCadila Pharnmaceuticals2017-06-08Not applicableUs
BudesonideSpray, metered32 ug/1NasalPar Pharmaceutical2014-10-212017-01-10Us
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Teva2008-11-19Not applicableUs
BudesonideInhalant.5 mg/2mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2017-01-20Not applicableUs
BudesonideCapsule3 mg/1OralMylan Pharmaceuticals2011-05-16Not applicableUs
BudesonideCapsule3 mg/1OralCarilion Materials Management2013-08-23Not applicableUs
BudesonideSuspension.25 mg/2mLRespiratory (inhalation)Sandoz2015-07-24Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BudesonideSpray, metered32 ug/1NasalApotex Corporation2016-04-19Not applicableUs
BudesonideSpray, metered32 ug/1NasalRite Aid2016-07-13Not applicableUs
BudesonideSpray, metered32 ug/1NasalWalmart2016-08-22Not applicableUs
BudesonideSpray, metered32 ug/1NasalAmerisource Bergen2016-09-15Not applicableUs
BudesonideSpray, metered32 ug/1NasalWalgreens2016-04-11Not applicableUs
BudesonideSpray, metered32 ug/1NasalRugby2016-07-13Not applicableUs
BudesonideSpray, metered32 ug/1NasalTopco Associates2016-08-31Not applicableUs
BudesonideSpray, metered32 ug/1NasalSafeway2016-09-15Not applicableUs
BudesonideSpray, metered32 ug/1NasalApotex Corporation2018-04-26Not applicableUs
BudesonideSpray, metered32 ug/1NasalCVS Health2016-04-09Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Entocort EnemaBudesonide (2.3 mg) + Sodium Chloride (115 ml)Enema; Kit; TabletRectalTillotts Pharma Gmbh1994-12-31Not applicableCanada
SymbicortBudesonide (80 ug/1) + Formoterol fumarate (4.5 ug/1)AerosolRespiratory (inhalation)Astra Zeneca Lp2007-05-29Not applicableUs
SymbicortBudesonide (160 ug/1) + Formoterol fumarate (4.5 ug/1)AerosolRespiratory (inhalation)Remedy Repack2016-04-042017-02-23Us
SymbicortBudesonide (160 ug/1) + Formoterol fumarate (4.5 ug/1)AerosolRespiratory (inhalation)A S Medication Solutions2007-05-292017-06-20Us
SymbicortBudesonide (160 ug/1) + Formoterol fumarate (4.5 ug/1)AerosolRespiratory (inhalation)Astra Zeneca Lp2007-05-29Not applicableUs
Symbicort 100 TurbuhalerBudesonide (100 mcg) + Formoterol fumarate (6 mcg)PowderRespiratory (inhalation)Astra Zeneca2002-02-08Not applicableCanada
Symbicort 200 TurbuhalerBudesonide (200 mcg) + Formoterol fumarate (6 mcg)PowderRespiratory (inhalation)Astra Zeneca2002-02-08Not applicableCanada
Symbicort Forte TurbuhalerBudesonide (400 mcg) + Formoterol fumarate (12 mcg)PowderRespiratory (inhalation)Astra ZenecaNot applicableNot applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Budesonide/formoterol TevaBudesonide (160 μg / dose) + Formoterol fumarate (4.5 μg / dose)Respiratory (inhalation)Teva Pharma B.V.2014-11-192017-01-31Eu
Budesonide/formoterol TevaBudesonide (320 μg / dose) + Formoterol fumarate (9 μg / dose)Respiratory (inhalation)Teva Pharma B.V.2014-11-192017-01-31Eu
International/Other Brands
Bidien / Budeson / Budicort / ENTOCORT / Noex (Eurofarma) / Pulmicort (AstraZeneca) / Rhinocort (AstraZeneca) / Rhinosol / Spirocort
Categories
UNII
Q3OKS62Q6X
CAS number
51333-22-3
Weight
Average: 430.5339
Monoisotopic: 430.23553882
Chemical Formula
C25H34O6
InChI Key
VOVIALXJUBGFJZ-KWVAZRHASA-N
InChI
InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-16-one
SMILES
[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication

The oral capsule is used for the treatment of mild to moderate active Crohn's disease. The oral tablet is used for induction of remission in patients with active, mild to moderate ulcerative colitis. The oral inhalation formulation is used for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.

Associated Conditions
Pharmacodynamics

Budesonide has a high glucocorticoid effect and a weak mineralocorticoid effect. It binds to the glucocorticoid receptor with a higher binding affinity than cortisol and prednisolone. When budesonide is systemically administered, suppression of endogenous cortisol concentrations and an impairment of the hypothalamus-pituitary-adrenal (HPA) axis function has been observed. Furthermore, a decrease in airway reactivity to histamine and other entities has been observed with the inhaled formulation. Generally, the inhaled formulation has a rapid onset action and improvement in asthma control can occur within 24 hours of initiation of treatment.

Mechanism of action

Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. The precise mechanism of corticosteroid actions on inflammation in asthma, Crohn's disease, or ulcerative colitis is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic and non-allergic-mediated inflammation. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in the aforementioned diseases. Because budesonide undergoes significant first-pass elimination, the both oral preparations are formulated as an extended release tablet. As a result, budesonide release is delyaed until exposure to a pH ≥ 7 in the small intestine.

TargetActionsOrganism
AGlucocorticoid receptor
antagonist
Human
Absorption

Absorption is complete following oral administration. The pharmacokinetic parameters of the inhaled powder formulation are as follows: Tmax = 30 minutes; Absolute systemic availability = 39%. When a single oral administration of 9 mg of Uceris are given, the pharmacokinetic parameters are as follows: Tmax = 13.3 ± 5.9 hours; Cmax = 1.35 ± 0.96 ng/mL; AUC = 16.43 ± 10.52 ng·hr/mL. It is important to note that the parameters have a high degree of variability. When a single oral administration of Entocort EC are given, the pharmacokinetic parameters are as follows: Tmax = 3- 600 minutes; Cmax = 5 nmol/L; AUC = 30 nmol•hr/L.

Volume of distribution

Tablet and capsule, healthy subjects and patients = 2.2 - 3.9 L/kg; Powder, metered = 3 L/kg

Protein binding

85-90% protein bound.

Metabolism

Following absorption, budesonide is subject to high first pass metabolism (80-90%). Budesonide is rapidly and extensively biotransformed, mainly by CYP3A4, to its 2 major metabolites, 6b-hydroxybudesonide and 16a- hydroxyprednisolone. The glucocorticoid activity of these metabolites is negligible (<1/100) in relation to that of the parent compound.

Route of elimination

Budesonide is excreted in urine and feces in the form of metabolites. Approximately 60% of an intravenous radiolabelled dose was recovered in the urine. No unchanged budesonide was detected in the urine.

Half life

Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn’s disease.

Clearance

Plasma clearance, tablet = 0.9 - 1.8 L/min; Systemic clearance, powder, 22R = 1.4 L/min; Systemic clearance, powder, 22S = 1.0 L/min; 0.5 L/min [Athmatic children 4 to 6 years of age]

Toxicity

Single oral doses of 200 and 400 mg/kg were lethal in female and male mice, respectively. The signs of acute toxicity were decreased motor activity, piloerection and generalized edema.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
T-box transcription factor TBX21---(C;G)CG allele (heterozygotes)Effect Directly StudiedThe presence of this polymorphism in TBX21 may be associated with improved responsiveness to budenoside for the treatment of asthma.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Budesonide.Experimental, Illicit, Investigational
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Budesonide.Experimental
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Budesonide.Investigational
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Budesonide.Experimental, Illicit
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Budesonide.Investigational
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Budesonide is combined with 2-Methoxyethanol.Experimental
4-HydroxytestosteroneThe risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Budesonide.Experimental, Illicit
5-androstenedioneThe risk or severity of edema formation can be increased when 5-androstenedione is combined with Budesonide.Experimental, Illicit
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Budesonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.Investigational
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Budesonide.Approved
AbediterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Abediterol.Investigational
AbetimusThe risk or severity of adverse effects can be increased when Budesonide is combined with Abetimus.Investigational
AceclofenacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Budesonide.Approved, Vet Approved
ActeosideThe risk or severity of adverse effects can be increased when Budesonide is combined with Acteoside.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Budesonide.Approved
AfelimomabThe risk or severity of adverse effects can be increased when Budesonide is combined with Afelimomab.Investigational
AlclofenacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Alclometasone.Approved
AlcuroniumThe risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Budesonide.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Budesonide is combined with Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Budesonide is combined with Aldosterone.Experimental, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Budesonide is combined with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Budesonide.Approved, Investigational
AlfacalcidolThe therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Budesonide.Approved, Nutraceutical
AlmasilateThe bioavailability of Budesonide can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Alminoprofen.Experimental
AloglutamolThe bioavailability of Budesonide can be decreased when combined with Aloglutamol.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Budesonide.Experimental
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Budesonide.Approved
AluminiumThe bioavailability of Budesonide can be decreased when combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe bioavailability of Budesonide can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Budesonide can be decreased when combined with Aluminium glycinate.Experimental
Aluminium phosphateThe bioavailability of Budesonide can be decreased when combined with Aluminium phosphate.Approved, Investigational
Aluminum hydroxideThe bioavailability of Budesonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
AmbenoniumThe therapeutic efficacy of Ambenonium can be decreased when used in combination with Budesonide.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Amcinonide.Approved
AminophenazoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Budesonide.Approved
AmiodaroneThe serum concentration of Budesonide can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BThe risk or severity of hypokalemia can be increased when Budesonide is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Budesonide can be increased when it is combined with Amprenavir.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Budesonide.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Budesonide.Approved
AndrostenediolThe risk or severity of edema formation can be increased when Androstenediol is combined with Budesonide.Experimental, Illicit
AndrostenedioneThe risk or severity of edema formation can be increased when Androstenedione is combined with Budesonide.Experimental, Illicit
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Budesonide.Approved
Anthrax vaccineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Budesonide.Approved
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Budesonide.Approved
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Budesonide.Approved, Investigational
AntipyrineThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Antipyrine.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Budesonide.Approved
AntrafenineThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Budesonide can be decreased when it is combined with Apalutamide.Approved, Investigational
ApremilastThe risk or severity of adverse effects can be increased when Budesonide is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Budesonide can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Arbutamine.Approved
ArformoterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Arformoterol.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Budesonide.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Budesonide is combined with Arsenic trioxide.Approved, Investigational
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Budesonide.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of edema formation can be increased when Atamestane is combined with Budesonide.Investigational
AtazanavirThe serum concentration of Budesonide can be increased when it is combined with Atazanavir.Approved, Investigational
AtracuriumThe risk or severity of myopathy and weakness can be increased when Atracurium is combined with Budesonide.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Budesonide.Approved
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Budesonide.Approved, Investigational
AzapropazoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Azapropazone.Withdrawn
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Budesonide.Approved
AzosemideThe risk or severity of hypokalemia can be increased when Budesonide is combined with Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Budesonide.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Budesonide.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Budesonide.Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Budesonide.Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Budesonide.Approved
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Budesonide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Budesonide.Approved, Investigational
BambuterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Bambuterol.Approved, Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Budesonide.Approved, Investigational
BCG vaccineThe risk or severity of infection can be increased when BCG vaccine is combined with Budesonide.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Budesonide.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Budesonide is combined with Beclomethasone dipropionate.Approved, Investigational
BecocalcidiolThe therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Budesonide.Investigational
BegelomabThe risk or severity of adverse effects can be increased when Budesonide is combined with Begelomab.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Budesonide.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Budesonide.Approved
BelinostatThe risk or severity of adverse effects can be increased when Budesonide is combined with Belinostat.Approved, Investigational
BendamustineThe risk or severity of adverse effects can be increased when Budesonide is combined with Bendamustine.Approved, Investigational
BendazacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Bendazac.Experimental
BendroflumethiazideBudesonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Benoxaprofen.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Budesonide.Approved, Investigational
BenzthiazideBudesonide may increase the hypokalemic activities of Benzthiazide.Approved
BenzydamineThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Benzydamine.Approved
BesifloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Besifloxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Budesonide.Approved, Vet Approved
BevacizumabThe risk or severity of adverse effects can be increased when Budesonide is combined with Bevacizumab.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Budesonide is combined with Bexarotene.Approved, Investigational
Bismuth subnitrateThe bioavailability of Budesonide can be decreased when combined with Bismuth subnitrate.Approved
BitolterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Bitolterol.Withdrawn
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Budesonide.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Budesonide is combined with Blinatumomab.Approved, Investigational
BoceprevirThe serum concentration of Budesonide can be increased when it is combined with Boceprevir.Approved, Withdrawn
BolandiolThe risk or severity of edema formation can be increased when Bolandiol is combined with Budesonide.Experimental, Illicit
BolasteroneThe risk or severity of edema formation can be increased when Bolasterone is combined with Budesonide.Experimental, Illicit
BoldenoneThe risk or severity of edema formation can be increased when Boldenone is combined with Budesonide.Illicit, Vet Approved
BortezomibThe risk or severity of adverse effects can be increased when Budesonide is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Budesonide can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe risk or severity of adverse effects can be increased when Budesonide is combined with Bosutinib.Approved
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Budesonide is combined with Brentuximab vedotin.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Budesonide is combined with Briakinumab.Investigational
BrigatinibThe serum concentration of Budesonide can be decreased when it is combined with Brigatinib.Approved, Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Budesonide is combined with Brodalumab.Approved, Investigational
BromfenacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Bromfenac.Approved
BufexamacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Bufexamac.Approved, Experimental
BumadizoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Bumadizone.Experimental
BumetanideThe risk or severity of hypokalemia can be increased when Budesonide is combined with Bumetanide.Approved
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Budesonide.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Budesonide is combined with Cabazitaxel.Approved
CalcidiolThe therapeutic efficacy of Calcidiol can be decreased when used in combination with Budesonide.Approved, Nutraceutical
CalcipotriolThe therapeutic efficacy of Calcipotriol can be decreased when used in combination with Budesonide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Budesonide.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Budesonide can be decreased when combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe bioavailability of Budesonide can be decreased when combined with Calcium silicate.Experimental
CalusteroneThe risk or severity of edema formation can be increased when Calusterone is combined with Budesonide.Experimental, Illicit
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Budesonide.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Budesonide.Approved, Investigational
Capromab pendetideBudesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Budesonide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Budesonide.Experimental, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Budesonide.Approved
CarfilzomibThe risk or severity of adverse effects can be increased when Budesonide is combined with Carfilzomib.Approved, Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Budesonide.Approved, Investigational
CarprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Budesonide is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of hypokalemia can be increased when Budesonide is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Budesonide can be increased when it is combined with Ceritinib.Approved
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Budesonide.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Budesonide.Approved
ChloramphenicolThe risk or severity of adverse effects can be increased when Budesonide is combined with Chloramphenicol.Approved, Vet Approved
ChlormadinoneThe serum concentration of Budesonide can be increased when it is combined with Chlormadinone.Experimental
ChlorothiazideBudesonide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneBudesonide may increase the hypokalemic activities of Chlorthalidone.Approved
CholecalciferolThe therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Budesonide.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Ciclesonide.Approved, Investigational
CimicoxibThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Cimicoxib.Investigational
CinoxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Ciprofloxacin.Approved, Investigational
CisatracuriumThe risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Budesonide.Approved
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Budesonide.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Budesonide.Approved, Investigational
ClarithromycinThe serum concentration of Budesonide can be increased when it is combined with Clarithromycin.Approved
ClenbuterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Budesonide is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Budesonide is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Budesonide is combined with Clocortolone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Budesonide.Approved, Investigational
ClonixinThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Clonixin.Approved
CloprednolThe risk or severity of adverse effects can be increased when Budesonide is combined with Cloprednol.Experimental
ClostebolThe risk or severity of edema formation can be increased when Clostebol is combined with Budesonide.Experimental, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Budesonide.Approved
ClotrimazoleThe serum concentration of Budesonide can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Budesonide.Approved, Investigational
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Budesonide.Approved
CorticotropinThe risk or severity of adverse effects can be increased when Budesonide is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Budesonide is combined with Cortisone acetate.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Budesonide is combined with Cortivazol.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Budesonide.Approved
CoumaphosThe therapeutic efficacy of Coumaphos can be decreased when used in combination with Budesonide.Vet Approved
CrizotinibThe serum concentration of Budesonide can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Budesonide can be increased when it is combined with Curcumin.Approved, Investigational
CyclopenthiazideBudesonide may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Budesonide.Approved, Investigational
CyclosporineThe serum concentration of Budesonide can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Budesonide.Approved, Investigational
DabrafenibThe serum concentration of Budesonide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Budesonide.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Budesonide.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Budesonide.Approved, Investigational
DanazolThe serum concentration of Budesonide can be increased when it is combined with Danazol.Approved
DarunavirThe serum concentration of Budesonide can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Budesonide can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Budesonide.Approved
DecamethoniumThe risk or severity of myopathy and weakness can be increased when Decamethonium is combined with Budesonide.Approved
DecitabineThe risk or severity of adverse effects can be increased when Budesonide is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Budesonide can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Budesonide is combined with Deflazacort.Approved, Investigational
DelavirdineThe serum concentration of Budesonide can be increased when it is combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Demecarium can be decreased when used in combination with Budesonide.Approved
DenosumabThe risk or severity of adverse effects can be increased when Budesonide is combined with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Budesonide is combined with Deoxyspergualin.Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Budesonide.Investigational
DesogestrelThe serum concentration of Budesonide can be increased when it is combined with Desogestrel.Approved
DesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Desoximetasone.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Budesonide is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Dexketoprofen.Approved, Investigational
DexrazoxaneThe risk or severity of adverse effects can be increased when Budesonide is combined with Dexrazoxane.Approved, Withdrawn
DichlorvosThe therapeutic efficacy of Dichlorvos can be decreased when used in combination with Budesonide.Vet Approved
DiclofenacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Diclofenac.Approved, Vet Approved
DienogestThe risk or severity of edema formation can be increased when Dienogest is combined with Budesonide.Approved
DifenpiramideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Diflorasone.Approved
DifloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Budesonide.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Budesonide is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Budesonide is combined with Difluprednate.Approved
DihydrotachysterolThe therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Budesonide.Approved
DiltiazemThe serum concentration of Budesonide can be increased when it is combined with Diltiazem.Approved, Investigational
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Budesonide is combined with Dimethyl fumarate.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Budesonide is combined with Dinutuximab.Approved, Investigational
DipivefrinThe risk or severity of hypokalemia can be increased when Budesonide is combined with Dipivefrin.Approved
DistigmineThe therapeutic efficacy of Distigmine can be decreased when used in combination with Budesonide.Experimental
DobutamineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Budesonide is combined with Docetaxel.Approved, Investigational
DonepezilThe therapeutic efficacy of Donepezil can be decreased when used in combination with Budesonide.Approved
DoxacuriumThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Budesonide.Approved
DoxercalciferolThe therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Budesonide.Approved
DoxifluridineThe risk or severity of adverse effects can be increased when Budesonide is combined with Doxifluridine.Investigational
DoxofyllineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Doxofylline.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Budesonide.Approved, Investigational
DoxycyclineThe serum concentration of Budesonide can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Budesonide can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe serum concentration of Budesonide can be increased when it is combined with Drospirenone.Approved
DroxicamThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Droxicam.Withdrawn
DroxidopaThe risk or severity of hypokalemia can be increased when Budesonide is combined with Droxidopa.Approved, Investigational
EchothiophateThe therapeutic efficacy of Echothiophate can be decreased when used in combination with Budesonide.Approved
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Budesonide.Approved, Investigational
EdrophoniumThe therapeutic efficacy of Edrophonium can be decreased when used in combination with Budesonide.Approved
EfalizumabThe risk or severity of adverse effects can be increased when Budesonide is combined with Efalizumab.Approved, Investigational
EfavirenzThe serum concentration of Budesonide can be increased when it is combined with Efavirenz.Approved, Investigational
EldecalcitolThe therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Budesonide.Investigational
ElocalcitolThe therapeutic efficacy of Elocalcitol can be decreased when used in combination with Budesonide.Investigational
EnoxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Budesonide can be decreased when it is combined with Enzalutamide.Approved
EphedraThe risk or severity of hypokalemia can be increased when Budesonide is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Epinephrine.Approved, Vet Approved
EpirizoleThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Epirizole.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Budesonide.Approved
EpitizideBudesonide may increase the hypokalemic activities of Epitizide.Experimental
ErgocalciferolThe therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Budesonide.Approved, Nutraceutical
EribulinThe risk or severity of adverse effects can be increased when Budesonide is combined with Eribulin.Approved, Investigational
ErythromycinThe serum concentration of Budesonide can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EstradiolThe serum concentration of Budesonide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Budesonide.Approved, Investigational
Etacrynic acidThe risk or severity of hypokalemia can be increased when Budesonide is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Etafedrine.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Budesonide.Approved, Investigational
EthenzamideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Budesonide can be increased when it is combined with Ethinyl Estradiol.Approved
EthynodiolThe serum concentration of Budesonide can be increased when it is combined with Ethynodiol.Experimental
Ethynodiol diacetateThe serum concentration of Budesonide can be increased when it is combined with Ethynodiol diacetate.Approved
EtodolacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Etofenamate.Approved, Investigational
EtonogestrelThe serum concentration of Budesonide can be increased when it is combined with Etonogestrel.Approved, Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Budesonide.Approved
EtoricoxibThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Budesonide can be decreased when it is combined with Etravirine.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Budesonide.Approved
FelbinacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Felbinac.Experimental
FenbufenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Fenbufen.Approved
FenoprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Fenoprofen.Approved
FenoterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Fenoterol.Approved, Investigational
FenthionThe therapeutic efficacy of Fenthion can be decreased when used in combination with Budesonide.Vet Approved
FentiazacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Feprazone.Experimental
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Budesonide.Approved, Investigational
FirocoxibThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Firocoxib.Experimental, Vet Approved
FleroxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Budesonide.Approved
FluasteroneThe risk or severity of edema formation can be increased when Fluasterone is combined with Budesonide.Investigational
FlucloroloneThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluclorolone.Experimental
FluconazoleThe serum concentration of Budesonide can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe risk or severity of adverse effects can be increased when Budesonide is combined with Flucytosine.Approved, Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Budesonide.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Budesonide.Approved, Investigational
FlumequineThe risk or severity of tendinopathy can be increased when Budesonide is combined with Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Budesonide is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Budesonide.Approved
FluoxymesteroneThe risk or severity of fluid retention can be increased when Budesonide is combined with Fluoxymesterone.Approved, Illicit
FluperoloneThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluperolone.Experimental
FluprednideneThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Budesonide is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Budesonide is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Budesonide can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of edema formation can be increased when Formestane is combined with Budesonide.Approved, Investigational, Withdrawn
FormocortalThe risk or severity of adverse effects can be increased when Budesonide is combined with Formocortal.Experimental
FormoterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Budesonide can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Budesonide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Budesonide can be increased when combined with Fosphenytoin.Approved, Investigational
FurosemideThe risk or severity of hypokalemia can be increased when Budesonide is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Budesonide can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Budesonide.Investigational
GalantamineThe therapeutic efficacy of Galantamine can be decreased when used in combination with Budesonide.Approved
GallamineThe risk or severity of myopathy and weakness can be increased when Gallamine is combined with Budesonide.Experimental
Gallamine TriethiodideThe risk or severity of myopathy and weakness can be increased when Gallamine Triethiodide is combined with Budesonide.Approved
Gallium nitrateThe risk or severity of adverse effects can be increased when Budesonide is combined with Gallium nitrate.Approved, Investigational
GarenoxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Gatifloxacin.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Budesonide.Approved
GemifloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Budesonide.Approved, Investigational
GestodeneThe serum concentration of Budesonide can be increased when it is combined with Gestodene.Approved, Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Budesonide.Investigational
Ginkgo bilobaThe therapeutic efficacy of Ginkgo biloba can be decreased when used in combination with Budesonide.Approved, Investigational, Nutraceutical
GlatiramerThe risk or severity of adverse effects can be increased when Glatiramer is combined with Budesonide.Approved, Investigational
GLPG-0492The risk or severity of fluid retention can be increased when Budesonide is combined with GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Budesonide.Approved
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Budesonide.Approved
GrepafloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Budesonide.Experimental
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Budesonide.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Halcinonide.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Halometasone.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Budesonide.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Budesonide.Approved, Withdrawn
HexoprenalineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Hexoprenaline.Approved, Withdrawn
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Budesonide.Approved
Huperzine AThe therapeutic efficacy of Huperzine A can be decreased when used in combination with Budesonide.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Budesonide.Approved, Investigational
HydrochlorothiazideBudesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Budesonide.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Budesonide.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Budesonide is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Budesonide is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Budesonide is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Budesonide is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Budesonide is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Budesonide is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroflumethiazideBudesonide may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Budesonide can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
HydroxychloroquineThe risk or severity of adverse effects can be increased when Budesonide is combined with Hydroxychloroquine.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Budesonide.Approved
HypericinThe risk or severity of adverse effects can be increased when Budesonide is combined with Hypericin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Budesonide.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Budesonide is combined with Ibrutinib.Approved
IbuprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Ibuproxam.Withdrawn
IcosapentThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Icosapent.Approved, Nutraceutical
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Budesonide.Approved
IdelalisibThe serum concentration of Budesonide can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Budesonide.Approved
ImatinibThe serum concentration of Budesonide can be increased when it is combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Imidazole salicylate.Experimental
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Budesonide.Approved, Investigational
IndacaterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Indacaterol.Approved
IndapamideBudesonide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Budesonide can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Indobufen.Investigational
IndomethacinThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Indoprofen.Withdrawn
InecalcitolThe therapeutic efficacy of Inecalcitol can be decreased when used in combination with Budesonide.Experimental, Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Budesonide.Approved
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Budesonide.Investigational
Interferon alfa-n3The risk or severity of adverse effects can be increased when Budesonide is combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Budesonide is combined with Interferon alfacon-1.Approved, Investigational
IpidacrineThe therapeutic efficacy of Ipidacrine can be decreased when used in combination with Budesonide.Experimental
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Budesonide.Approved, Investigational
IsavuconazoleThe serum concentration of Budesonide can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Budesonide can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoetarineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Isoetarine.Approved
IsoflurophateThe therapeutic efficacy of Isoflurophate can be decreased when used in combination with Budesonide.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Budesonide can be increased when it is combined with Isoniazid.Approved, Investigational
IsoprenalineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Isoprenaline.Approved, Investigational
IsoxicamThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Isoxicam.Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Budesonide.Investigational
ItraconazoleThe serum concentration of Budesonide can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Budesonide can be increased when it is combined with Ivacaftor.Approved
IxabepiloneThe risk or severity of adverse effects can be increased when Budesonide is combined with Ixabepilone.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Budesonide.Approved
KebuzoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Kebuzone.Experimental
KetoconazoleThe serum concentration of Budesonide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Ketorolac.Approved
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Budesonide.Approved, Investigational, Nutraceutical
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Budesonide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Budesonide.Approved
LevofloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe serum concentration of Budesonide can be increased when it is combined with Levonorgestrel.Approved, Investigational
LevosalbutamolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Budesonide is combined with Linezolid.Approved, Investigational
LomefloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Lomefloxacin.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Budesonide.Approved, Investigational
LonazolacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Lonazolac.Experimental
LopinavirThe serum concentration of Budesonide can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Budesonide can be increased when it is combined with Lorpiprazole.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Budesonide is combined with Loteprednol.Approved
LovastatinThe serum concentration of Budesonide can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe therapeutic efficacy of Budesonide can be decreased when used in combination with Loxapine.Approved
LoxoprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Loxoprofen.Approved, Investigational
LuliconazoleThe serum concentration of Budesonide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Budesonide can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Lumiracoxib.Approved, Investigational
LynestrenolThe serum concentration of Budesonide can be increased when it is combined with Lynestrenol.Approved, Investigational
MagaldrateThe bioavailability of Budesonide can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe bioavailability of Budesonide can be decreased when combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe bioavailability of Budesonide can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe bioavailability of Budesonide can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Budesonide can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Magnesium salicylate.Approved
Magnesium silicateThe bioavailability of Budesonide can be decreased when combined with Magnesium silicate.Approved
Magnesium TrisilicateThe bioavailability of Budesonide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Malathion can be decreased when used in combination with Budesonide.Approved, Investigational
MaxacalcitolThe therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Budesonide.Approved, Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Budesonide.Approved, Investigational
Meclofenamic acidThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Meclofenamic acid.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Budesonide can be increased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Mefenamic acid.Approved
MefloquineThe therapeutic efficacy of Mefloquine can be decreased when used in combination with Budesonide.Approved, Investigational
Megestrol acetateThe serum concentration of Budesonide can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Budesonide is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Meloxicam.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Budesonide.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Budesonide.Approved, Investigational
MeprednisoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Meprednisone.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Budesonide.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Budesonide.Approved
MesteroloneThe risk or severity of edema formation can be increased when Mesterolone is combined with Budesonide.Experimental
MetamizoleThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Metamizole.Approved, Investigational, Withdrawn
MetenoloneThe risk or severity of edema formation can be increased when Metenolone is combined with Budesonide.Experimental
Methanesulfonyl FluorideThe therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Budesonide.Investigational
MethimazoleThe risk or severity of adverse effects can be increased when Budesonide is combined with Methimazole.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Budesonide.Approved
MethyclothiazideBudesonide may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Budesonide.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Budesonide.Approved, Vet Approved
MethyltestosteroneThe risk or severity of edema formation can be increased when Methyltestosterone is combined with Budesonide.Approved
MetoclopramideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Budesonide.Approved, Investigational
MetocurineThe risk or severity of myopathy and weakness can be increased when Metocurine is combined with Budesonide.Approved
Metocurine IodideThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Budesonide.Approved, Withdrawn
MetolazoneBudesonide may increase the hypokalemic activities of Metolazone.Approved
MibefradilThe serum concentration of Budesonide can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiboleroneThe risk or severity of edema formation can be increased when Mibolerone is combined with Budesonide.Vet Approved
MiconazoleThe serum concentration of Budesonide can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Budesonide.Approved, Experimental
MifepristoneThe serum concentration of Budesonide can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe therapeutic efficacy of Minaprine can be decreased when used in combination with Budesonide.Approved
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Budesonide.Approved
MitotaneThe serum concentration of Budesonide can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Budesonide.Approved, Investigational
MivacuriumThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Budesonide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Budesonide is combined with Mizoribine.Investigational
ModafinilThe serum concentration of Budesonide can be decreased when it is combined with Modafinil.Approved, Investigational
MofebutazoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Budesonide is combined with Mometasone furoate.Approved, Vet Approved
MorniflumateThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Morniflumate.Approved
MoxifloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Moxifloxacin.Approved, Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Budesonide.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Budesonide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Budesonide.Approved
NabumetoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Nabumetone.Approved
NafcillinThe serum concentration of Budesonide can be decreased when it is combined with Nafcillin.Approved, Investigational
Nalidixic AcidThe risk or severity of tendinopathy can be increased when Budesonide is combined with Nalidixic Acid.Approved, Investigational
NaloxoneThe serum concentration of Budesonide can be increased when it is combined with Naloxone.Approved, Vet Approved
NandroloneThe risk or severity of edema formation can be increased when Nandrolone is combined with Budesonide.Experimental, Investigational
Nandrolone decanoateThe risk or severity of edema formation can be increased when Nandrolone decanoate is combined with Budesonide.Approved, Illicit
Nandrolone phenpropionateThe risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Budesonide.Approved, Illicit, Investigational
NaproxenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Naproxen.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Budesonide.Approved, Investigational
NefazodoneThe serum concentration of Budesonide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Budesonide is combined with Nelarabine.Approved, Investigational
NelfinavirThe serum concentration of Budesonide can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Nemonoxacin.Investigational
NeosaxitoxinThe risk or severity of myopathy and weakness can be increased when Neosaxitoxin is combined with Budesonide.Investigational
NeostigmineThe therapeutic efficacy of Neostigmine can be decreased when used in combination with Budesonide.Approved, Vet Approved
NepafenacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Nepafenac.Approved, Investigational
NetupitantThe serum concentration of Budesonide can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Budesonide can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Budesonide can be increased when it is combined with Nicardipine.Approved, Investigational
NicorandilThe risk or severity of ulceration can be increased when Budesonide is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Niflumic Acid.Approved
NilotinibThe serum concentration of Budesonide can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Budesonide.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Budesonide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Budesonide.Investigational
NomegestrolThe serum concentration of Budesonide can be increased when it is combined with Nomegestrol.Approved
NorelgestrominThe serum concentration of Budesonide can be increased when it is combined with Norelgestromin.Approved, Investigational
NorepinephrineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Norepinephrine.Approved
NorethisteroneThe serum concentration of Budesonide can be increased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Norfloxacin.Approved
NorgestimateThe serum concentration of Budesonide can be increased when it is combined with Norgestimate.Approved, Investigational
NorgestrelThe serum concentration of Budesonide can be increased when it is combined with Norgestrel.Approved
NorgestrienoneThe serum concentration of Budesonide can be increased when it is combined with Norgestrienone.Experimental
NS-398The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with NS-398.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Budesonide is combined with Obinutuzumab.Approved, Investigational
OcrelizumabThe risk or severity of adverse effects can be increased when Budesonide is combined with Ocrelizumab.Approved, Investigational
OfloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Ofloxacin.Approved
OlaparibThe serum concentration of Budesonide can be increased when it is combined with Olaparib.Approved
OlodaterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Olodaterol.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Budesonide.Approved
OrbifloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Orbifloxacin.Vet Approved
OrciprenalineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Orciprenaline.Approved
OsimertinibThe serum concentration of Budesonide can be increased when it is combined with Osimertinib.Approved
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Budesonide.Approved, Investigational
OxandroloneThe risk or severity of fluid retention can be increased when Budesonide is combined with Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Oxaprozin.Approved
Oxolinic acidThe risk or severity of tendinopathy can be increased when Budesonide is combined with Oxolinic acid.Experimental
OxymetholoneThe risk or severity of fluid retention can be increased when Budesonide is combined with Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Budesonide is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Budesonide can be increased when it is combined with Palbociclib.Approved, Investigational
PancuroniumThe risk or severity of myopathy and weakness can be increased when Pancuronium is combined with Budesonide.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Budesonide is combined with Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Paramethasone.Approved
ParaoxonThe therapeutic efficacy of Paraoxon can be decreased when used in combination with Budesonide.Experimental
ParecoxibThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Parecoxib.Approved
ParicalcitolThe therapeutic efficacy of Paricalcitol can be decreased when used in combination with Budesonide.Approved, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Budesonide is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Budesonide.Approved, Investigational
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Budesonide is combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Budesonide is combined with Peginterferon alfa-2b.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Budesonide.Approved, Investigational
PentobarbitalThe metabolism of Budesonide can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Budesonide.Approved, Investigational
PF-00610355The risk or severity of hypokalemia can be increased when Budesonide is combined with PF-00610355.Investigational
PhenobarbitalThe metabolism of Budesonide can be increased when combined with Phenobarbital.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Budesonide.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Budesonide.Approved
PhenylbutazoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Phenylbutazone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Budesonide.Approved, Investigational
PhenylpropanolamineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Budesonide can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Physostigmine can be decreased when used in combination with Budesonide.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Budesonide is combined with Pimecrolimus.Approved, Investigational
PipecuroniumThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Budesonide.Approved
Pipemidic acidThe risk or severity of tendinopathy can be increased when Budesonide is combined with Pipemidic acid.Experimental
PirarubicinThe risk or severity of adverse effects can be increased when Budesonide is combined with Pirarubicin.Investigational
PirbuterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Pirbuterol.Approved
PiretanideThe risk or severity of hypokalemia can be increased when Budesonide is combined with Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Budesonide is combined with Pirfenidone.Approved, Investigational
Piromidic acidThe risk or severity of tendinopathy can be increased when Budesonide is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Pirprofen.Experimental
PitolisantThe serum concentration of Budesonide can be decreased when it is combined with Pitolisant.Approved, Investigational
PolythiazideBudesonide may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Budesonide.Approved
PonatinibThe risk or severity of adverse effects can be increased when Budesonide is combined with Ponatinib.Approved, Investigational
PosaconazoleThe serum concentration of Budesonide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Budesonide is combined with Pralatrexate.Approved, Investigational
PranoprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of edema formation can be increased when Prasterone is combined with Budesonide.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of edema formation can be increased when Prasterone sulfate is combined with Budesonide.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Budesonide is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Budesonide.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Budesonide.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Budesonide is combined with Prednylidene.Experimental
PrimidoneThe metabolism of Budesonide can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Budesonide.Approved, Investigational
ProcaterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Procaterol.Approved, Investigational
ProglumetacinThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Propacetamol.Approved, Investigational
PropylthiouracilThe risk or severity of adverse effects can be increased when Budesonide is combined with Propylthiouracil.Approved, Investigational
PropyphenazoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Proquazone.Experimental
ProtokylolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Protokylol.Approved, Vet Approved
PrulifloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Prulifloxacin.Investigational
PyrantelThe risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Budesonide.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Budesonide.Approved, Investigational
QuinethazoneBudesonide may increase the hypokalemic activities of Quinethazone.Approved
QuingestanolThe serum concentration of Budesonide can be increased when it is combined with Quingestanol.Experimental
QuinineThe metabolism of Budesonide can be increased when combined with Quinine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Budesonide.Approved, Investigational
RacepinephrineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Racepinephrine.Approved
RaltitrexedThe risk or severity of adverse effects can be increased when Budesonide is combined with Raltitrexed.Approved, Investigational
RapacuroniumThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Budesonide.Withdrawn
RibociclibThe serum concentration of Budesonide can be increased when it is combined with Ribociclib.Approved, Investigational
RifampicinThe metabolism of Budesonide can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Budesonide can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Budesonide can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Budesonide can be increased when combined with Rifaximin.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Budesonide.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Budesonide.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Budesonide is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Budesonide.Investigational
RisperidoneThe serum concentration of Budesonide can be increased when it is combined with Risperidone.Approved, Investigational
RitodrineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Budesonide can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Budesonide.Approved
RivastigmineThe therapeutic efficacy of Rivastigmine can be decreased when used in combination with Budesonide.Approved, Investigational
RobenacoxibThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Robenacoxib.Experimental, Vet Approved
RocuroniumThe risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Budesonide.Approved
RofecoxibThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Rofecoxib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Budesonide.Approved
RosoxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Budesonide.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Budesonide.Approved, Investigational
RufloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Rufloxacin.Experimental
RuxolitinibThe risk or severity of adverse effects can be increased when Budesonide is combined with Ruxolitinib.Approved
SalbutamolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Salbutamol.Approved, Vet Approved
SalicylamideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Budesonide.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of hypokalemia can be increased when Budesonide is combined with Salmeterol.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Budesonide.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of infection can be increased when Salmonella typhi Ty21a live antigen is combined with Budesonide.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Budesonide.Approved
SalsalateThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Salsalate.Approved
SaquinavirThe serum concentration of Budesonide can be increased when it is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Sarafloxacin.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Budesonide can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Budesonide.Approved
SC-236The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with SC-236.Experimental, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Budesonide.Approved
SeocalcitolThe therapeutic efficacy of Seocalcitol can be decreased when used in combination with Budesonide.Experimental, Investigational
SiltuximabThe serum concentration of Budesonide can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Budesonide can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Budesonide.Approved, Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Budesonide.Approved, Investigational
SitafloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Budesonide can be decreased when combined with Sodium bicarbonate.Approved
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Budesonide.Approved, Investigational
SparfloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Sparfloxacin.Approved, Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Budesonide.Investigational
St. John's WortThe serum concentration of Budesonide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe risk or severity of edema formation can be increased when Stanolone is combined with Budesonide.Illicit, Investigational
StanozololThe risk or severity of fluid retention can be increased when Budesonide is combined with Stanozolol.Approved, Vet Approved
SteproninThe risk or severity of adverse effects can be increased when Budesonide is combined with Stepronin.Approved
StiripentolThe serum concentration of Budesonide can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Budesonide.Approved, Investigational
SuccinylcholineThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Budesonide.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Budesonide is combined with Sulfasalazine.Approved
SulindacThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Sulindac.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Budesonide is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Suxibuzone.Experimental
TacalcitolThe therapeutic efficacy of Tacalcitol can be decreased when used in combination with Budesonide.Experimental, Investigational
TacrineThe therapeutic efficacy of Tacrine can be decreased when used in combination with Budesonide.Investigational, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Budesonide.Approved, Investigational
TalniflumateThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Talniflumate.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Budesonide.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Technetium Tc-99m ciprofloxacin.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Budesonide is combined with Tedizolid phosphate.Approved
TelaprevirThe serum concentration of Budesonide can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Budesonide can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Temafloxacin.Withdrawn
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Budesonide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Budesonide is combined with Temsirolimus.Approved
TenidapThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Tenidap.Experimental
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Budesonide.Approved
TenoxicamThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Budesonide is combined with Tepoxalin.Vet Approved
TerbutalineThe risk or severity of hypokalemia can be increased when Budesonide is combined with Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Budesonide.Approved
TestosteroneThe risk or severity of edema formation can be increased when Testosterone is combined with Budesonide.Approved, Investigational
Testosterone cypionateThe risk or severity of edema formation can be increased when Testosterone cypionate is combined with Budesonide.Approved
Testosterone enantate benzilic acid hydrazoneThe risk or severity of edema formation can be increased when Testosterone enantate benzilic acid hydrazone is combined with Budesonide.Approved, Experimental
Testosterone enanthateThe risk or severity of edema formation can be increased when Testosterone enanthate is combined with Budesonide.Approved
Testosterone propionateThe risk or severity of edema formation can be increased when Testosterone propionate is combined with Budesonide.Approved, Investigational, Vet Approved, Withdrawn
Testosterone succinateThe risk or severity of edema formation can be increased when Testosterone succinate is combined with Budesonide.Experimental
Testosterone undecanoateThe risk or severity of edema formation can be increased when Testosterone undecanoate is combined with Budesonide.Approved, Investigational
TetrandrineThe risk or severity of adverse effects can be increased when Budesonide is combined with Tetrandrine.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Budesonide.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Budesonide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Budesonide.Approved, Investigational
Tiaprofenic acidThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Tiaprofenic acid.Approved
TinoridineThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Tinoridine.Investigational
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Budesonide.Approved
TipranavirThe serum concentration of Budesonide can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Budesonide is combined with Tixocortol.Approved, Withdrawn
TocilizumabThe serum concentration of Budesonide can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Budesonide.Approved, Investigational
TofacitinibBudesonide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Tolmetin.Approved
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Budesonide.Approved, Investigational
TorasemideThe risk or severity of hypokalemia can be increased when Budesonide is combined with Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Budesonide.Approved, Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Budesonide is combined with Trabectedin.Approved, Investigational
TrastuzumabThe risk or severity of adverse effects can be increased when Budesonide is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Budesonide is combined with Trastuzumab emtansine.Approved, Investigational
TrestoloneThe risk or severity of edema formation can be increased when Trestolone is combined with Budesonide.Investigational
Trestolone acetateThe risk or severity of edema formation can be increased when Trestolone acetate is combined with Budesonide.Experimental
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Budesonide.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Budesonide.Approved, Vet Approved
TrichlorfonThe therapeutic efficacy of Trichlorfon can be decreased when used in combination with Budesonide.Vet Approved
TrichlormethiazideBudesonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Budesonide is combined with Trifluridine.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Budesonide is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TriptolideThe risk or severity of adverse effects can be increased when Budesonide is combined with Triptolide.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Budesonide is combined with Trofosfamide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Budesonide.Approved
TroleandomycinThe serum concentration of Budesonide can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of tendinopathy can be increased when Budesonide is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of myopathy and weakness can be increased when Tubocurarine is combined with Budesonide.Approved
Typhoid VaccineThe therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Budesonide.Approved
TyrothricinThe therapeutic efficacy of Tyrothricin can be decreased when used in combination with Budesonide.Approved
UlipristalThe serum concentration of Budesonide can be increased when it is combined with Ulipristal.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Budesonide is combined with Ulobetasol.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Budesonide.Approved, Investigational
ValdecoxibThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Valdecoxib.Approved, Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/Attenuated) is combined with Budesonide.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Budesonide.Approved
VecuroniumThe risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Budesonide.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Budesonide.Approved
VemurafenibThe serum concentration of Budesonide can be decreased when it is combined with Vemurafenib.Approved
VerapamilThe serum concentration of Budesonide can be increased when it is combined with Verapamil.Approved
Vibrio cholerae CVD 103-HgR strain live antigenThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Budesonide.Approved, Investigational
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Budesonide.Approved, Investigational
VilanterolThe risk or severity of adverse effects can be increased when Budesonide is combined with Vilanterol.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Budesonide.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Budesonide.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Budesonide.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Budesonide.Approved, Investigational
Vitamin DThe therapeutic efficacy of Vitamin D can be decreased when used in combination with Budesonide.Approved, Nutraceutical, Vet Approved
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Budesonide.Investigational
VoriconazoleThe serum concentration of Budesonide can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Budesonide is combined with Vorinostat.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be increased when used in combination with Budesonide.Approved
WortmanninThe risk or severity of adverse effects can be increased when Budesonide is combined with Wortmannin.Experimental
Yellow Fever VaccineThe risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Budesonide.Approved, Investigational
Yellow Fever VaccineThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Budesonide.Approved, Investigational
ZaltoprofenThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe risk or severity of adverse effects can be increased when Budesonide is combined with Zidovudine.Approved
ZiprasidoneThe serum concentration of Budesonide can be increased when it is combined with Ziprasidone.Approved
ZomepiracThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Zomepirac.Withdrawn
Food Interactions
  • A mean delay in time to peak concentration of 2.5 hours is observed with the intake of a high-fat meal, with no significant differences in AUC.

References

Synthesis Reference

Peter Gruber, Hans Joachim Lach, Norbert Otterbeck, "Budesonide pellets with a controlled released pattern and process for producing the same." U.S. Patent US5932249, issued May, 1991.

US5932249
General References
Not Available
External Links
Human Metabolome Database
HMDB0015353
KEGG Drug
D00246
PubChem Compound
5281004
PubChem Substance
46504869
ChemSpider
4444479
BindingDB
50354850
ChEBI
3207
ChEMBL
CHEMBL1370
Therapeutic Targets Database
DAP000320
PharmGKB
PA448681
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Budesonide
ATC Codes
R03AK07 — Formoterol and budesonideA07EA06 — BudesonideR03BA02 — BudesonideR01AD05 — BudesonideD07AC09 — BudesonideR03AK12 — Salmeterol and budesonide
AHFS Codes
  • 68:04.00 — Adrenals
  • 52:08.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (52.3 KB)
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceAsthma Bronchial1
1CompletedPreventionAcute Chest Syndrome / Asthma Bronchial / Sickle Cell Disorders1
1CompletedTreatmentAllergies1
1CompletedTreatmentAsthma Bronchial6
1CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)2
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentGraft Versus Host Disease (GVHD) / Transplantation, Stem Cell1
1CompletedTreatmentLiver Cirrhosis, Biliary / Sclerosing Cholangitis1
1CompletedTreatmentSnoring1
1RecruitingHealth Services ResearchHealthy Volunteers1
1, 2CompletedTreatmentAsthma Bronchial1
1, 2RecruitingPreventionBronchopulmonary Dysplasia (BPD)1
2Active Not RecruitingTreatmentOesophagitis, Eosinophilic1
2CompletedNot AvailableAsthma Bronchial1
2CompletedPreventionAcute Respiratory Distress Syndrome (ARDS)1
2CompletedPreventionLung Cancers2
2CompletedTreatmentAllergic Rhinitis (AR)1
2CompletedTreatmentAllogeneic Stem Cell Transplantation / Obliterative Bronchiolitis1
2CompletedTreatmentAsthma Bronchial5
2CompletedTreatmentBronchial Asthma1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)4
2CompletedTreatmentCopd Bronchitis1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentEosinophilic Esophagitis (EoE)1
2CompletedTreatmentExercised Induced Asthma1
2CompletedTreatmentIgA Nephropathy1
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentObstructive Airway Disease1
2CompletedTreatmentOesophagitis, Eosinophilic3
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)3
2CompletedTreatmentStable Asthma1
2CompletedTreatmentUlcerative Colitis (UC)1
2RecruitingTreatmentAcute Cellular Graft Rejection / New Onset Diabetes After Transplant1
2RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2RecruitingTreatmentCrohn's Disease (CD)1
2RecruitingTreatmentDiarrhea1
2RecruitingTreatmentEarly Stage HER2+ Breast Cancer1
2RecruitingTreatmentEsophageal Strictures1
2TerminatedPreventionCryptogenic Organizing Pneumonia / Lung Diseases, Interstitial / Obliterative Bronchiolitis / Respiratory Tract Infections (RTI)1
2TerminatedPreventionProphylaxis of Radiation proctitis1
2TerminatedTreatmentInflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
2Unknown StatusPreventionChronic Lung Disease of Prematurity1
2Unknown StatusTreatmentTransient Tachypnea of the Newborn1
2WithdrawnTreatmentGraft Versus Host Disease, Acute / Intestinal Graft Versus Host Disease1
2WithdrawnTreatmentOlfaction Disorders / Paranasal Sinus Diseases / Sinusitis1
2, 3CompletedTreatmentAllergies1
2, 3CompletedTreatmentEE / Gastro-esophageal Reflux Disease (GERD) / Gastroesophageal Reflux Disease / Oesophagitis, Eosinophilic1
2, 3CompletedTreatmentHepatitis, Autoimmune1
2, 3CompletedTreatmentPolyps, Nasal1
2, 3CompletedTreatmentSinusitis1
2, 3CompletedTreatmentStatus Asthmaticus1
2, 3Not Yet RecruitingTreatmentChronic Rhinosinusitis / Chronic Sinus Congestion / Chronic Sinus Infection / Chronic Sinusitis - Ethmoidal, Posterior1
2, 3TerminatedTreatmentDiarrhea / Lymphocytic Colitis1
3Active Not RecruitingTreatmentAcute maxillary sinusitis caused by M. catarrhalis1
3CompletedNot AvailableAsthma Bronchial1
3CompletedPreventionChronic Lung Disease of Prematurity1
3CompletedPreventionGraft Versus Host Disease (GVHD) / Leukemias1
3CompletedPreventionOther and unspecified effects of high altitude1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAsthma Bronchial44
3CompletedTreatmentAsthma Bronchial / Chronic Lung Diseases1
3CompletedTreatmentCOPD Patients1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)7
3CompletedTreatmentChronic Obstructive Pulmonary Disorder2
3CompletedTreatmentChronic / Chronic Rhinosinusitis / Polyposis / Sinusitis1
3CompletedTreatmentCollagenous Colitis2
3CompletedTreatmentCrohn's Disease (CD)4
3CompletedTreatmentGraft Versus Host Disease (GVHD)1
3CompletedTreatmentInduction and Maintaining Remission of Collagenous Colitis1
3CompletedTreatmentLymphocytic Colitis1
3CompletedTreatmentMicroscopic Colitis1
3CompletedTreatmentMild or Moderate Asthma1
3CompletedTreatmentOesophagitis, Eosinophilic1
3CompletedTreatmentOral Chronic Graft vs Host Disease1
3CompletedTreatmentProctitis / Proctosigmoiditis2
3CompletedTreatmentPulmonary Disease, Chronic Obstructive1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentUlcerative Colitis (UC)4
3Not Yet RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
3Not Yet RecruitingTreatmentRhinitis, Allergic, Perennial2
3RecruitingTreatmentAcute maxillary sinusitis caused by M. catarrhalis / Chronic Polyposis1
3RecruitingTreatmentAsthma Bronchial1
3RecruitingTreatmentAsthma Bronchial / Bioequivalence1
3RecruitingTreatmentAsthma, Allergic1
3RecruitingTreatmentBronchial Asthma1
3RecruitingTreatmentChronic Rhinosinusitis (Diagnosis), Nasal Polyposis1
3RecruitingTreatmentChronic Rhinosinusitis With Nasal Polyps1
3RecruitingTreatmentEosinophilic Esophagitis (EoE)1
3RecruitingTreatmentEosinophilic Esophagitis (EoE) / Oesophagitis, Eosinophilic1
3TerminatedTreatmentPrimary Biliary Cirrhosis (PBC)1
3Unknown StatusTreatmentBronchial Asthma1
3Unknown StatusTreatmentCollagenous Colitis1
3Unknown StatusTreatmentEmphysema / Poor Sleeping Quality1
3WithdrawnPreventionAltitude Sickness1
4Active Not RecruitingTreatmentOesophagitis, Eosinophilic1
4CompletedNot AvailableAsthma Bronchial1
4CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
4CompletedBasic ScienceMild Asthma1
4CompletedSupportive CareAsthma Bronchial1
4CompletedTreatmentAcute maxillary sinusitis caused by M. catarrhalis / Allergic Rhinosinusitis / Chronic Eosinophilic Rhinosinusitis1
4CompletedTreatmentAllergic Rhinitis (AR)1
4CompletedTreatmentAsthma Acute / Asthma Bronchial / Reactive Airway Exacerbation1
4CompletedTreatmentAsthma Bronchial12
4CompletedTreatmentBronchial Asthma1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)10
4CompletedTreatmentCrohn's Disease (CD)1
4CompletedTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
4CompletedTreatmentOesophagitis, Eosinophilic1
4CompletedTreatmentPerennial Allergic Rhinitis (PAR)2
4CompletedTreatmentPulmonary Disease, Chronic Obstructive1
4Not Yet RecruitingPreventionChronic Lung Disease of Prematurity / Respiratory Distress Syndrome (RDS)1
4Not Yet RecruitingPreventionChronic Obstructive Pulmonary Disease (COPD) / Lung Cancers / Post Operative Complication, Pulmonary1
4Not Yet RecruitingPreventionExposure to Pollution / Glucocorticoid Resistance1
4Not Yet RecruitingTreatmentAsthma Bronchial1
4Not Yet RecruitingTreatmentPulmonary Disease, Chronic Obstructive1
4RecruitingNot AvailableAsthma Bronchial1
4RecruitingPreventionChronic Lung Disease of Prematurity / Infants, Premature / Respiratory Distress Syndrome (RDS)1
4RecruitingTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentAsthma Bronchial1
4RecruitingTreatmentAsthma Bronchial / Pediatric ALL1
4RecruitingTreatmentAsthma-chronic obstructive pulmonary disease overlap syndrome / Pulmonary Disease, Chronic Obstructive / Quality of Life / Small Airway Disease1
4RecruitingTreatmentBronchial Asthma1
4RecruitingTreatmentBronchiectasis / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentExercise / Lung Function Decreased / Pulmonary Disease, Chronic Obstructive / Quality of Life1
4RecruitingTreatmentHyposmia1
4RecruitingTreatmentPulmonary Disease, Chronic Obstructive1
4RecruitingTreatmentPulmonary Disease,Chronic Obstructive1
4RecruitingTreatmentSevere IgE-mediated Asthma1
4TerminatedTreatmentAsthma Bronchial1
4TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
4TerminatedTreatmentExercised Induced Asthma1
4Unknown StatusPreventionChronic Lung Disease of Prematurity / Respiratory Distress Syndrome (RDS)1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4Unknown StatusTreatmentObstructive Sleep Apnea (OSA)1
4WithdrawnNot AvailableBone destruction1
4WithdrawnBasic ScienceAsthma Bronchial1
4WithdrawnTreatmentAcute Cellular Graft Rejection / Liver Transplant Rejection1
4WithdrawnTreatmentAsthma Bronchial2
Not AvailableActive Not RecruitingNot AvailableCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)1
Not AvailableActive Not RecruitingBasic ScienceAsthma Bronchial1
Not AvailableActive Not RecruitingTreatmentAsthma Bronchial1
Not AvailableCompletedNot AvailableAsthma Bronchial3
Not AvailableCompletedNot AvailableAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailablePerception of Physicians & Patients of AMD1
Not AvailableCompletedNot AvailableUlcerative Colitis (UC)1
Not AvailableCompletedBasic ScienceAsthma Bronchial2
Not AvailableCompletedDiagnosticAsthma Bronchial1
Not AvailableCompletedHealth Services ResearchAsthma Bronchial1
Not AvailableCompletedTreatmentAsthma Bronchial1
Not AvailableCompletedTreatmentAsthma Bronchial / Chronic Lung Diseases1
Not AvailableCompletedTreatmentChronic Rhinosinusitis / Nasal Polyposis1
Not AvailableCompletedTreatmentPolyps, Nasal / Sinusitis1
Not AvailableCompletedTreatmentRespiratory Distress Syndrome (RDS)1
Not AvailableRecruitingNot AvailableAsthma Bronchial2
Not AvailableRecruitingPreventionAcute Exacerbation of Chronic Obstructive Pulmonary Disease / Air Pollution1
Not AvailableTerminatedTreatmentAsthma Bronchial1
Not AvailableTerminatedTreatmentChronic Rhinosinusitis1
Not AvailableTerminatedTreatmentColitis1
Not AvailableUnknown StatusNot AvailableAllergic Rhinitis (AR) / Asthma Bronchial1
Not AvailableUnknown StatusNot AvailableFocus of Study is to Improve Asthma Control Based on Phenotype, NO and Sputum Cell Count1
Not AvailableUnknown StatusPreventionRespiratory Sounds2
Not AvailableUnknown StatusTreatmentAsthma Bronchial2
Not AvailableUnknown StatusTreatmentStridor1
Not AvailableWithdrawnTreatmentHepatitis, Autoimmune / Primary Biliary Cirrhosis (PBC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • 3M Health Care
  • A-S Medication Solutions LLC
  • Astra Pharma Inc.
  • AstraZeneca Inc.
  • Dispensing Solutions
  • Galderma Laboratories
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Physicians Total Care Inc.
  • Prometheus Laboratories Inc.
  • Redpharm Drug
  • Spectrum Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
Dosage forms
FormRouteStrength
CapsuleOral3 mg/1
Capsule, coated pelletsOral3 mg/1
Capsule, gelatin coatedOral3 mg/1
InhalantRespiratory (inhalation).25 mg/2mL
InhalantRespiratory (inhalation).5 mg/2mL
Spray, meteredNasal32 ug/1
SuspensionRespiratory (inhalation).25 mg/2mL
SuspensionRespiratory (inhalation).5 mg/2mL
Tablet, film coated, extended releaseOral9 mg/1
Capsule, delayed release pelletsOral3 mg/1
InhalantOral.25 mg/2mL
InhalantOral.5 mg/2mL
InhalantOral1 mg/2mL
Tablet, extended releaseOral9 mg
Capsule, extended releaseOral3 mg
Enema; kit; tabletRectal
Spray, meteredNasal100 mcg
Spray, meteredNasal64 mcg
Aerosol, powderRespiratory (inhalation)180 ug/1
Aerosol, powderRespiratory (inhalation)90 ug/1
SuspensionRespiratory (inhalation)0.125 mg
SuspensionRespiratory (inhalation)0.25 mg
SuspensionRespiratory (inhalation)0.5 mg
SuspensionRespiratory (inhalation)1 mg/2mL
Aerosol, metered; powderRespiratory (inhalation)100 mcg
Aerosol, metered; powderRespiratory (inhalation)200 mcg
Aerosol, metered; powderRespiratory (inhalation)400 mcg
Aerosol, meteredNasal100 mcg
PowderNasal; Respiratory (inhalation)100 mcg
AerosolRespiratory (inhalation)
PowderRespiratory (inhalation)
Aerosol, foamRectal28 mg/1
Tablet, extended releaseOral9 mg/1
Prices
Unit descriptionCostUnit
Budesonide micronized powder346.5USD g
DesOwen Lot w/Cetaphil Cream 0.05% Kit Box255.84USD box
Desowen 0.05% ointment kit217.2USD kit
Desowen 0.05% cream kit212.4USD kit
DesOwen 0.05% Lotion 118ml Bottle183.17USD bottle
Pulmicort Flexhaler 180 mcg/act Aerosol Inhaler163.34USD inhaler
Pulmicort 180 mcg flexhaler157.06USD inhaler
DesOwen 0.05% Lotion 59ml Bottle123.38USD bottle
Pulmicort Flexhaler 90 mcg/act Aerosol Inhaler121.98USD inhaler
Pulmicort 90 mcg flexhaler117.29USD inhaler
Rhinocort Aqua 32 mcg/act 8.6 gm Bottle111.96USD bottle
Rhinocort aqua nasal spray13.93USD g
Entocort EC 3 mg 24 Hour Capsule13.86USD capsule
Entocort ec 3 mg capsule12.22USD capsule
Budesonide 0.5 mg/2ml Suspension 2ml Plastic Container9.73USD plastic
Pulmicort 0.5 mg/2ml Suspension 2ml Plastic Container9.24USD plastic
Budesonide 0.25 mg/2ml Suspension 2ml Plastic Container9.07USD plastic
Entocort (115 Ml) 2.3 mg/enm Enema8.93USD enema
Pulmicort 1 mg/2 ml respule8.89USD ml
Pulmicort 0.25 mg/2ml Suspension 2ml Plastic Container7.85USD plastic
Pulmicort 0.5 mg/2 ml respule4.45USD ml
Pulmicort 0.25 mg/2 ml respul3.78USD ml
Desowen 0.05% cream2.43USD g
Pulmicort Nebuamp 0.5 mg/ml Suspension0.93USD ml
Pulmicort Turbuhaler 400 mcg/dose Metered Inhalation Powder0.62USD dose
Pulmicort Nebuamp 0.25 mg/ml Suspension0.46USD ml
Pulmicort Turbuhaler 200 mcg/dose Metered Inhalation Powder0.34USD dose
Pulmicort Nebuamp 0.125 mg/ml Suspension0.23USD ml
Pulmicort Turbuhaler 100 mcg/dose Metered Inhalation Powder0.17USD dose
Rhinocort Turbuhaler 100 mcg/dose Metered Dose Aerosol0.13USD dose
Mylan-Budesonide Aq 100 mcg/dose Metered Dose Spray0.1USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6423340No1993-11-152010-11-15Us
CA2071518No2002-11-122010-11-15Canada
US6598603Yes1999-06-232019-06-23Us
US6899099Yes1999-06-232019-06-23Us
US7524834Yes1999-05-112019-05-11Us
US7759328Yes2003-07-292023-07-29Us
US7897646Yes1999-03-092019-03-09Us
US8143239Yes2003-07-292023-07-29Us
US8461211Yes1999-03-092019-03-09Us
US8575137Yes2003-07-292023-07-29Us
US6123924No1997-09-262017-09-26Us
US7967011Yes2002-02-112022-02-11Us
US8616196Yes2009-10-072029-10-07Us
US8387615Yes2005-05-102025-05-10Us
US7587988Yes2006-10-102026-10-10Us
US7367333Yes1999-05-112019-05-11Us
US8528545Yes2009-04-162029-04-16Us
US8875699Yes2005-05-102025-05-10Us
US6027714No1998-01-092018-01-09Us
US7143764No1998-03-132018-03-13Us
US6142145No1998-05-082018-05-08Us
US6287540No1998-01-092018-01-09Us
US9320716No2000-06-092020-06-09Us
US9192581No2011-09-072031-09-07Us
US7410651No2000-06-092020-06-09Us
USRE43799No2000-06-092020-06-09Us
US8895064No2011-09-072031-09-07Us
US7431943No2000-06-092020-06-09Us
US9132093No2011-09-072031-09-07Us
US8784888No2000-06-092020-06-09Us
US8293273No2000-06-092020-06-09Us
US5914122No1995-12-192015-12-19Us
US9532954No2000-06-092020-06-09Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)226°CPhysProp
water solubilityinsolubleNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0457 mg/mLALOGPS
logP2.42ALOGPS
logP2.73ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.74ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.11 m3·mol-1ChemAxon
Polarizability47.11 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9872
Blood Brain Barrier+0.9533
Caco-2 permeable-0.6097
P-glycoprotein substrateSubstrate0.804
P-glycoprotein inhibitor INon-inhibitor0.5881
P-glycoprotein inhibitor IINon-inhibitor0.5911
Renal organic cation transporterNon-inhibitor0.7867
CYP450 2C9 substrateNon-substrate0.8488
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7337
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9075
CYP450 2D6 inhibitorNon-inhibitor0.9441
CYP450 2C19 inhibitorNon-inhibitor0.939
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8886
Ames testNon AMES toxic0.9117
CarcinogenicityNon-carcinogens0.9466
BiodegradationNot ready biodegradable0.9759
Rat acute toxicity2.1601 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Non-inhibitor0.5627
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03k9-1794300000-d4cdef973973a6b24ba4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-3950000000-8e98d604876730f53851

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Alpha-hydroxy ketones / 1,3-dioxolanes / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives
show 5 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / Delta-1,4-steroid
show 17 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
11beta-hydroxy steroid, glucocorticoid, cyclic acetal, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:3207)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Zhang X, Moilanen E, Kankaanranta H: Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol. 2000 Oct 20;406(3):325-32. [PubMed:11040338]
  2. Henriksson G, Norlander T, Forsgren J, Stierna P: Effects of topical budesonide treatment on glucocorticoid receptor mRNA down-regulation and cytokine patterns in nasal polyps. Am J Rhinol. 2001 Jan-Feb;15(1):1-8. [PubMed:11258648]
  3. Zhang X, Moilanen E, Kankaanranta H: Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol. 2001 Nov 23;431(3):365-71. [PubMed:11730731]
  4. Kompella UB, Bandi N, Ayalasomayajula SP: Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1192-201. [PubMed:12601049]
  5. Kunz S, Sandoval R, Carlsson P, Carlstedt-Duke J, Bloom JW, Miesfeld RL: Identification of a novel glucocorticoid receptor mutation in budesonide-resistant human bronchial epithelial cells. Mol Endocrinol. 2003 Dec;17(12):2566-82. Epub 2003 Aug 14. [PubMed:12920235]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Jonsson G, Astrom A, Andersson P: Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1995 Jan;23(1):137-42. [PubMed:7720517]
  3. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:50